EULAR

Celltrion’s Infliximab Biobetter Shows Significant Clinical Improvements Over Original Biosimilar Version

June 4th 2022

Article

Results from the European Congress of Rheumatology’s annual meeting revealed that Celltrion’s Remsima SC, a subcutaneous biobetter infliximab product, produced better clinical outcomes compared with the original Remsima, an infliximab biosimilar delivered intravenously.

Etanercept Reverse Switching Is Measured in Netherlands Study

June 4th 2021

Article

Investigators in the Netherlands observed that 13.7% of patients with rheumatic disease had switched back to etanercept originator at 4.4 years from baseline.

French Investigators Report Rituximab Immunogenicity Findings

June 3rd 2021

Article

Immunogenicity was rare but concerning for patients who switched from originator rituximab to the biosimilar Riximyo, investigators reported.

Poster Roundup: Results Presented for Samsung Bioepis Biosimilars for Adalimumab, Infliximab

June 2nd 2021

Article

Real-world clinical data compiled for patients with autoimmune disorders were presented at EULAR 2021.

Celltrion Supports High-Concentration Adalimumab Biosimilar Launch With Phase 3 Trial Data

June 2nd 2021

Article

Celltrion announces the launch timing for its much anticipated high-concentration formulation of adalimumab and presents trial data supporting equivalence to the reference product.

Looking Back, UK Patients Unhappy With Adalimumab Biosimilar Switch

June 24th 2020

Article

The UK results show how challenging switching to a biosimilar can be, according to patient groups.

EULAR Studies Explore Value of Biosimilar Switching

June 17th 2020

Article

Studies on switching and retention for adalimumab and etanercept biosimilars yielded positive data, according to abstracts presented at the EULAR 2020 Congress.

French Rheumatologists Lack Confidence in Biosimilars, Study Says

June 17th 2020

Article

A study presented at the European League Against Rheumatism conference suggested that French rheumatologists have good knowledge of biosimilars but lack the confidence to use them.

Celltrion's Infliximab Demonstrates Value in Trio of Studies

June 15th 2020

Article

The infliximab biosimilar CT-P13 delivered positive results in studies presented at the European League Against Rheumatism's European E-Congress of Rheumatology 2020.

Celltrion Presents More Data Showing Comparable Efficacy, Safety of Subcutaneous CT-P13 to IV Form

June 19th 2019

Article

Korean drug maker Celltrion Healthcare recently presented new findings from a 2-part study at the European League Against Rheumatism European Congress of Rheumatology 2019 meeting about subcutaneous biosimilar CT-P13 (Inflectra, Remsima).